Affiliation: GlaxoSmithKline Biologicals
- Modeling the impact of the difference in cross-protection data between a human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and a human papillomavirus (HPV)-6/11/16/18 vaccine in CanadaMichele Kohli
OptumInsight, Health Economics and Outcomes Research, 5500 North Service Rd, Burlington, ON L7L 6W6, Canada
BMC Public Health 12:872. 2012..In this analysis, the estimated clinical and economic benefit of each of these vaccines was compared in the Canadian setting...
- Incremental cost-effectiveness evaluation of vaccinating girls against cervical cancer pre- and post-sexual debut in BelgiumNadia Demarteau
Health Economics, GlaxoSmithKline Vaccines, Rue Fleming 20, B 1300 Wavre, Belgium
Vaccine 31:3962-71. 2013..The role of protection against non-HPV-16/18 was also investigated...
- Cost-effectiveness analysis of the bivalent compared with the quadrivalent human papillomavirus vaccines in TaiwanNadia Demarteau
GlaxoSmithKline Biologicals, Wavre, Belgium
Value Health 15:622-31. 2012....
- Selecting a mix of prevention strategies against cervical cancer for maximum efficiency with an optimization programNadia Demarteau
Health Economics, Global Vaccine Development, GlaxoSmithKline Biologicals, Wavre, Belgium
Pharmacoeconomics 30:337-53. 2012..Neither alone can provide 100% protection. Consequently it raises the important question about the most efficient combination of screening at specified time intervals and vaccination to prevent cervical cancer...
- A cost-utility analysis of cervical cancer vaccination in preadolescent Canadian femalesAndrea M Anonychuk
Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON, Canada
BMC Public Health 9:401. 2009..This study estimates the effectiveness and cost-effectiveness of vaccinating 12-year old Canadian females with an AS04-adjuvanted cervical cancer vaccine. The indirect effect of vaccination, via herd immunity, is also estimated...
- Human papillomavirus vaccine introduction in low-income and middle-income countries: guidance on the use of cost-effectiveness modelsMark Jit
Modelling and Economics Unit, Health Protection Agency, London, UK
BMC Med 9:54. 2011..To provide information about the feasibility of using such models in a developing country setting, we evaluated models of HPV vaccination in terms of their capacity, requirements, limitations and comparability...
- A generally applicable cost-effectiveness model for the evaluation of vaccines against cervical cancerNadia Demarteau
Health Economics, GlaxoSmithKline Biologicals, Wavre, Belgium
Int J Public Health 56:153-62. 2011..This study aimed at evaluating the cost-effectiveness of human papillomavirus virus (HPV) vaccination in France, using a generally applicable succinct cohort model...
- Modelling the economic value of cross- and sustained-protection in vaccines against cervical cancerNadia Demarteau
Health Economics, GlaxoSmithKline Biologicals, Av Fleming 20, Wavre, Belgium
J Med Econ 13:324-38. 2010..Two human papillomavirus (HPV) vaccines are on the market. Based on expected differences in sustained- and cross-protection between the two vaccines, their long-term economic value is modelled and compared for France, Ireland and Italy...
- Modelling the effect of conjugate vaccines in pneumococcal disease: cohort or population models?Baudouin Standaert
Health Economics, GlaxoSmithKline Biologicals, Parc de la Noire Epine, B 1300 Wavre, Belgium
Vaccine 28:G30-8. 2010....
- Estimation of the potential overall impact of human papillomavirus vaccination on cervical cancer cases and deathsGeorges Van Kriekinge
Health Economics, GlaxoSmithKline Vaccines, Avenue Fleming, 20, Wavre, 1300, Belgium Electronic address
Vaccine 32:733-9. 2014..Mathematical models have estimated the potential real-life impact of vaccination on the burden of cervical cancer (CC). However, these are restricted to evaluations in a limited number of countries...